• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

    11.15 -0.11 (-0.98%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 69,653
    Open 11.28
    Bid (Size) 10.20 (2,000)
    Ask (Size) 11.30 (600)
    Prev. Close 11.26
    Today's Range 11.09 - 11.30
    52wk Range 6.280 - 18.99
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    TLX101-Px (Pixlumi®) MAA Accepted in Europe
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire

    Performance

    YTD
    +46.3%
    +46.3%
    1 Month
    +22.1%
    +22.1%
    3 Month
    +50.1%
    +50.1%
    6 Month
    +7.3%
    +7.3%
    1 Year
    -40.4%
    -40.4%

    More News

    Read More
    News headline image
    OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    The Radiopharmaceutical Renaissance: A Deep Dive into Telix Pharmaceuticals (TLX)
    Via Finterra
    Topics Economy Initial Public Offering
    News headline image
    Telix and Regeneron Announce Strategic Radiopharma Collaboration
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Regeneron and Telix Announce Strategic Radiopharma Collaboration
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    FDA Accepts NDA for TLX101-Px (Pixclara®)
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Strengthens Board with Additional Director Appointments
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Appoints David Gill as Non-Executive Director
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Investor Education Webinar
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    1 Basically Unknown Stock That Could Turn Cancer‑Imaging Breakthroughs Into Generational Wealth ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Telix to Participate in Oppenheimer and TD Cowen Conferences
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Full Year Results 2025 Investor Webcast Notification
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights
    From Bragar Eagel & Squire
    Via GlobeNewswire

    Frequently Asked Questions

    Is Telix Pharmaceuticals Limited - American Depositary Shares publicly traded?
    Yes, Telix Pharmaceuticals Limited - American Depositary Shares is publicly traded.
    What exchange does Telix Pharmaceuticals Limited - American Depositary Shares trade on?
    Telix Pharmaceuticals Limited - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares?
    The ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares is TLX on the Nasdaq Stock Market
    What is the current price of Telix Pharmaceuticals Limited - American Depositary Shares?
    The current price of Telix Pharmaceuticals Limited - American Depositary Shares is 11.15
    When was Telix Pharmaceuticals Limited - American Depositary Shares last traded?
    The last trade of Telix Pharmaceuticals Limited - American Depositary Shares was at 05/04/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.